An interventional study of Probiotic in Inflammatory Bowel Disease, sponsored by Wecare Probiotics Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.
Sponsored by Wecare Probiotics Co., Ltd. · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 114 studies in Inflammatory Bowel Diseases with a site in China — 51 open to participants now, 55 under way, 5 of them phase 3. Inflammatory Bowel Diseases · China.
Among the 114 studies in Inflammatory Bowel Diseases with a site in China, this one is the 49th largest by enrollment of the 60 interventional ones that give a count, is one of 26 that started in 2025, is one of 28 with no phase, and was the 74th registered.
1,555 studies on the registry are indexed under Inflammatory Bowel Diseases; 425 are open to participants now.
Browse Inflammatory Bowel Diseases studies →51 of the 114 studies in Inflammatory Bowel Diseases with a site in China are open now. Recruiting first, the newest first:
Benethera (Shaoxing) Biotechnology Co., Ltd. · Sites in China
Ages 18–55 · Healthy volunteers
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–80
First Affiliated Hospital of Kunming Medical University · Sites in China
Ages 18–60
Changhai Hospital · Sites in China
Ages 18–75
InSilico Medicine Hong Kong Limited · Sites in China
Ages 18–75
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 276 Inflammatory Bowel Diseases studies recruiting now, 134 (49%) set no upper age limit and 114 (41%) stop at 75 or younger; 75 take children under 18; 60 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
114 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 14 · Phase 3 9
First in 2009; this study’s year is marked. 26 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 41 is below the median of 68 across 875 interventional studies indexed under Inflammatory Bowel Diseases.
Median enrollment 97 across the 60 interventional studies, 148 across the 54 observational. Of the 35 that completed or were terminated, 6 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 114 have an industry lead sponsor. The 10 most frequent:
Wecare Probiotics Co., Ltd. is the lead sponsor of 67 studies on the registry; 23 are open to participants now.
Wecare Probiotics Co., Ltd. has 1 study filed under Inflammatory Bowel Diseases — fewer than ten, so there is no comparison to draw.
13 of the studies in Inflammatory Bowel Diseases with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06713694Wang ZhenThe Impact of Culture in Cognitive Behavior Therapy (CBT) for Patients With Inflammatory Bowel Disease | 2026-12-30 |
| NCT07632573Benethera (Shaoxing) Biotechnology Co., Ltd.A Phase I Study to Evaluate the Safety/Tolerability of BDHK-2009 Tablets in Healthy Adult | 2026-12-31 |
| NCT07165470Changhai HospitalPre-Packaged Low-Residue Diet Assisting Bowel Preparation in Patients With Inflammatory Bowel Disease | 2026-12-31 |
| NCT06483373Shanghai Pharmaceuticals Holding Co., LtdA Clinical Study of SPH7854 Granules in Healthy Subjects. | 2026-12-31 |
| NCT04187820Shanghai Institute of Acupuncture, Moxibustion and MeridianEffect of Acupuncture on Mild to Moderate Active Crohn's Disease | 2026-12-31 |
Add all 13 to your calendar (.ics) → With an account.
Among the 114 studies in Inflammatory Bowel Diseases with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study evaluates oral Lactobacillus reuteri as an adjunct therapy for 2 months. Endoscopic assessments will be performed at baseline and after 2 months of intervention to evaluate intestinal inflammation. Intestinal fluid samples will be collected during endoscopy for 16S rRNA gene sequencing to assess changes in the gut microbiota. Peripheral blood inflammatory markers and fecal calprotectin levels will also be measured to evaluate changes in intestinal inflammation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Daily intervention with Limosilactobacillus reuteri LR08 (10 billion CFU) for 8 weeks, stored in a cool and dry place.
Dietary Supplement: Probiotic
The experimental phase of the study lasts 8 weeks and each patient will be visited 4 times.
Change in Intestinal Inflammation
Intestinal inflammation will be assessed using the Simple Endoscopic Score for Crohn's Disease (SES-CD) in patients with Crohn's disease and the Mayo Score in patients with ulcerative colitis. SES-CD scores range from 0 to 56, and Mayo scores range from 0 to 12. Higher scores indicate more severe disease activity.
Time frame: 8 weeks
Ran from Jan 2025 to primary completion in Mar 2026, 14 months.
Of 299 interventional studies with no phase under Inflammatory Bowel Diseases, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 50. This study's 14 months is below that.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 19, 2026: primary completion Oct 2025 → Mar 2026 and completion Dec 2025 → Jun 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Probiotic